Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that the management team will participate in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.
JERSEY, Channel Islands, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that the management team will participate in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. As part of the conference, the Company will be conducting a fireside chat on Thursday, February 17, 2022 at 8:00am ET.
BTIG hosted events are intended for prospective and existing BTIG clients only. To request a one-on-one meeting with management or to listen to the live event, please contact your BTIG representative with interest.
About Quotient Limited
Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and create operational cost savings to laboratories around the world. Quotient’s operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania.
The Quotient logo, Quotient MosaiQ and MosaiQ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.
Contact: IR@quotientbd.com; +41 22 545 52 26
